Hamburg - Delayed Quote EUR

Vertex Pharmaceuticals Inc (VX1.HM)

447.95

+25.75

+(6.10%)

As of 5:25:18 PM GMT+1. Market Open.

AbbVie, Vertex's Journavx, Exxon and Chevron: Market Minute

Yahoo Finance host Josh Lipton breaks down the day's top trending stocks and market stories in the Market Minute. AbbVie (ABBV) shares continue to pop in Friday trading after raising its revenue guidance for new drugs Skyrizi and Rinvoq. Vertex Pharmaceuticals (VRTX) stock is rising after receiving approval by the Food and Drug Administration (FDA) over its new non-opioid pain management drug, Journavx. Lastly, oil giants Exxon Mobil (XOM) and Chevron (CVX) move lower as the industry is monitoring the long-term impacts of President Trump's tariffs. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. This post was written by Luke Carberry Mogan.

Yahoo Finance Video 2 hours ago

CL=F

BZ=F

CVX
Vertex stock jumps on FDA approval of new non-opioid painkiller

Vertex Pharmaceuticals (VRTX) stock is rising following Food and Drug Administration (FDA) approval of Journavx, a non-opioid pain medication designed to treat moderate to severe acute pain. The new drug represents a potentially significant advancement in pain management, offering an alternative to traditional opioid-based treatments. Wealth anchor Brad Smith is joined by Seana Smith to break down the details. To watch more expert insights and analysis on the latest market action, check out more Wealth here. This post was written by Angel Smith

Yahoo Finance Video 2 hours ago

VRTX
These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More

Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, Intel edges higher after revenue projections miss analysts’ estimates, and Chevron posts adjusted earnings below expectations.

Barrons.com 2 hours ago

INTC

TEAM

DECK
How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter

Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.

Investor's Business Daily 2 hours ago

VRTX
No Major Catalyst, Wells Fargo Downgraded Vertex

The target price was adjusted to $460 which was reached today

GuruFocus.com 3 hours ago

VRTX

VERX
Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.

Barrons.com 3 hours ago

VRTX
VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up

The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.

Zacks 3 hours ago

VRTX
The FDA approved a new non-opioid painkiller. Its maker's stock is rising

Vertex Pharmaceuticals (VRTX) stock rose on Friday after the Food and Drug Administration (FDA) approved its new painkiller, the first of its kind approved by regulators.

Quartz 4 hours ago

VRTX
Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval

Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration.

Investopedia 4 hours ago

VRTX
Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller

Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.

Investor's Business Daily 5 hours ago

VRTX
NHS England to offer Casgevy for sickle cell disease patients

Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

Pharmaceutical Technology 7 hours ago

VRTX
FDA approves Vertex’s acute pain treatment Journavx

The FDA has approved the therapy for administration twice daily.

Pharmaceutical Technology 10 hours ago

VRTX
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

LONDON, January 31, 2025--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel).

Business Wire 12 hours ago

VRTX
Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug

Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug Administration approval.

The Wall Street Journal 19 hours ago

VRTX
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

BOSTON, January 30, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. JOURNAVX is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain.

Business Wire 20 hours ago

VRTX
Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX)’s Suzetrigine: ‘I Don’t See A Lot Of Upside Because That Was The Drug Of The Future For Vertex’

We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks Jim Cramer recently talked about. Jim Cramer, the host of Mad Money, has been considering the uncertainty surrounding 2025 and […]

Insider Monkey yesterday

VRTX
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks yesterday

VRTX
Vertex Pharmaceuticals (NASDAQ:VRTX) lifts 3.2% this week, taking five-year gains to 83%

The simplest way to invest in stocks is to buy exchange traded funds. But you can do a lot better than that by buying...

Simply Wall St. yesterday

VRTX
Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $440.68, marking a -0.72% move from the previous day.

Zacks 2 days ago

VRTX
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks 3 days ago

VRTX

Performance Overview

Return	VX1.HM	S&P 500
YTD	+15.11%	+2.49%
1-Year	+11.17%	+22.92%
3-Year	+118.62%	+36.60%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vertex Pharmaceuticals Inc (VX1.HM)

AbbVie, Vertex's Journavx, Exxon and Chevron: Market Minute

Vertex stock jumps on FDA approval of new non-opioid painkiller

These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More

How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter

No Major Catalyst, Wells Fargo Downgraded Vertex

Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller

VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up

The FDA approved a new non-opioid painkiller. Its maker's stock is rising

Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval

Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller

NHS England to offer Casgevy for sickle cell disease patients

FDA approves Vertex’s acute pain treatment Journavx

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX)’s Suzetrigine: ‘I Don’t See A Lot Of Upside Because That Was The Drug Of The Future For Vertex’

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Vertex Pharmaceuticals (NASDAQ:VRTX) lifts 3.2% this week, taking five-year gains to 83%

Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Performance Overview